



## ASX ANNOUNCEMENT

25 March 2021

### Strategic Advisor Appointments and UK Update

#### Key Points:

- Two highly experienced respiratory executives appointed to provide strategic advice to RespiRI Board
- Dr Andrew Weekes, Medical Director of GSK Australia
- Dr Mark Levy, member of GINA (Global Initiative for Asthma) Executive Board of Directors
- RespiRI advancing discussions as a key technology partner in several large UK studies in asthma

**RespiRI Limited (ASX:RSH) (“RespiRI” or the “Company”)**, an eHealth SaaS Company supporting respiratory health management, is pleased to announce the appointment of Dr Andrew Weekes as a strategic advisor to the RespiRI Board, effective 15 March 2021. The timing of this appointment seeks to align expert advice with additional initiatives undertaken to launch wheezo™ in the UK market in late 2021.

Dr Weekes is currently the Country Medical Director, Australia for GlaxoSmithKline (GSK; NYSE:GSK) and has led a number of major initiatives at GSK, including being the first pharmaceutical company in Australia to introduce a new framework for its medical education program and interactions with healthcare professionals. GSK is a leading global player in respiratory diseases, having recorded 2020 sales of £3.7 billion. Dr Weekes is a UK-trained doctor, with over 20 years’ experience in global or national roles in UK, France and Australasia, including for pharmaceutical companies AbbVie and Servier. In his role, Dr Weekes will provide advice to the Board pertaining to wheezo™ for its commercialisation, clinical development, R&D, key opinion leader introduction and relationship management for the Company.

Mr Marjan Mikel, CEO of RespiRI said “We are delighted that Andrew has accepted this advisory role to the Company. His substantial experience within a leading pharma company along with his global experience including the UK, harmonises with our preparations and plans for a UK launch, which have now commenced and remain on-track for a Q4 2021 launch in that important asthma market.”

Dr Weekes said “I’m delighted to have the opportunity to work with RespiRI given the strong team, solid tech, clear vision and commitment to research” “The Wheezo and associated app can support individuals living with asthma to better understand and engage with the condition, and actively manage it in conjunction with their doctor. RespiRI plan to build from this base with new evidence and complementary tech; all aimed at improving engagement, adherence and ultimately outcomes in airways disease.”

Plans for wheezo launch in the UK continue to progress with RespiRI in commercial discussions with Cipla and other potential partners. RespiRI recently appointed Dr Mark Levy as an advisor for the UK. Dr Levy has been a member of GINA (Global Initiative for Asthma) Executive Board or Directors since 2009. GINA is the preeminent body responsible for setting global treatment and management guidelines for asthma. Mikel stated “we are delighted to be reconnecting with Dr Levy, who is experienced in respiratory medicine, the way medical system works in the UK and the intricacies of working with the NHS to deliver world class care for patients and well connected in this therapeutic area both commercially and clinically. He has already provided us with invaluable advice and introductions as we plan to launch our organisation in the UK later in 2021.”

In addition, Respiro is in advanced discussions with key clinicians in the UK regarding participation as a key technology partner in several large asthma-related studies expected to provide key clinical evidence managing treatment decisions for the use of asthma therapeutics and the role of advanced digital technologies in the management of pediatric asthma in the UK. Such large studies will build awareness and educate clinicians in the UK and offer additional scientific evidence for inclusion into the asthma care quality standards issued by the National Institute for Health and Care Excellence (NICE), which state *“Monitoring asthma control and addressing any problems identified will improve quality of life and reduce the risk of serious asthma attacks and hospital admissions.”*<sup>1</sup>

- ENDS -

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiro Limited  
P: +61 408 462 873  
E: [marjan@respiro.co](mailto:marjan@respiro.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiro Limited  
P: +61 447 074 160  
E: [nicholas@respiro.co](mailto:nicholas@respiro.co)

™ wheezo is a trademark of Respiro Limited.

*This ASX announcement dated 25 March 2021 has been authorised for release by the Board of Directors of Respiro Limited.*

## About Respiro Limited

Respiro is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiro's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respiro's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiro Limited's operations are based in Melbourne, Australia.

For additional information about Respiro and its products, please visit [www.respiro.co](http://www.respiro.co)

## About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo, follow the online link <https://wheezo.com>

---

<sup>1</sup> <https://www.nice.org.uk/guidance/qs25/resources/asthma-pdf-2098547456965>

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.